Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | EDNRB | P24530 | 3/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8212482 | 0.92 | POLB (0.36) | NPC1CYP17A1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL4017282 | 0.87 | HDAC6 (0.44) | NPC1CYP17A1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL4011948 | 0.86 | PDE4B (0.34) | NPC1CYP17A1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL4519628 | 0.86 | ALDH1A1 (0.36) | CYP17A1CYP19A1CYP11B1CYP11B2PDE4B | |
| SCHEMBL4524475 | 0.83 | PDE4B (0.34) | CYP17A1CYP19A1CYP11B1CYP11B2PDE4B | |
| SCHEMBL4017828 | 0.81 | TNKS (0.35) | NPC1CYP17A1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL8201409 | 0.81 | POLB (0.43) | NPC1HDAC6ALDH1A1HSD17B10KDM4E | |
| SCHEMBL4016542 | 0.80 | CYP19A1 (0.37) | NPC1CYP17A1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL4513853 | 0.79 | ALDH1A1 (0.43) | CYP17A1CYP19A1CYP11B1CYP11B2HDAC6 | |
| SCHEMBL14856886 | 0.79 | HSD17B10 (0.34) | NPC1CYP17A1CYP19A1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074106-B1 | DIBENZOFURAN DERIVATIVES AS INHIBITORS OF PDE-4 AND PDE-10 | MYLAN LAB LTD (IN) | 2013-04-17 | — | — | EP | claimed |
| US-8263648-B2 | Diebenzofuran derivatives as inhibitors of PDE-4 and PDE-10 | Mylan Laboratories Ltd. (IN) | 2012-09-11 | — | — | US | claimed |
| EP-2074106-B1 | DIBENZOFURAN DERIVATIVES AS INHIBITORS OF PDE-4 AND PDE-10 | MYLAN LAB LTD (IN) | 2013-04-17 | — | — | EP | disclosed |
| US-8263648-B2 | Diebenzofuran derivatives as inhibitors of PDE-4 and PDE-10 | Mylan Laboratories Ltd. (IN) | 2012-09-11 | — | — | US | disclosed |
| US-20090281131-A1 | DIEBENZOFURAN DERIVATIVES AS INHIBITORS OF PDE-4 AND PDE-10 | MYLAN LABORATORIES LIMITED (IN) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281131-A1 | DIEBENZOFURAN DERIVATIVES AS INHIBITORS OF PDE-4 AND PDE-10 | PDE4A, PDE4B, PDE12 | NPC1 4500/4885CYP17A1 521/4885CYP19A1 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.